February 12, 2026 10:54 AM
Shorter all-oral regimens for drug-resistant TB cost-effective in India: ICMR study
Shorter, six-month all-oral treatment regimens for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are cost-effective and offer better health outcomes compared to the longer regimens currently in use in India, according to a study conducted by the ICMR–National Institute for Research in Tuberculosis (ICMR-NIRT). The study, published in the Indian Journal of Medical Research, assessed the cost-effectiveness of bedaquiline-based regimens — BPaL (bedaquiline, pretomanid a...


